- Alirocumab is a monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme involved in cholesterol regulation. It is used as an adjunct to diet and statin therapy to lower low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia, heterozygous familial hypercholesterolemia (HeFH), or clinical atherosclerotic cardiovascular disease (ASCVD)
- The global alirocumab market is experiencing steady growth due to the increasing prevalence of cardiovascular diseases, rising cholesterol-related health concerns, and growing awareness of PCSK9 inhibitors
- North America is expected to dominate the alirocumab market with a market share of approximately 40.4%, driven by the high prevalence of cardiovascular diseases, increased awareness of lipid-lowering therapies, and the strong presence of key pharmaceutical companies such as Sanofi and Regeneron
- Asia-Pacific is expected to be the fastest growing region in the alirocumab market, with a projected market share of approximately 24.6% in 2025, driven by the rapid expansion of healthcare infrastructure, increasing prevalence of cardiovascular diseases, and growing awareness of cholesterol-lowering therapies
- Adult patients segment is expected to dominate the market with a market share of 72.15% due to the higher prevalence of cardiovascular diseases and hypercholesterolemia in the adult population. As these conditions are more common in adults, particularly those aged 40 and above, there is a significant demand for lipid-lowering therapies such as alirocumab
